Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.[1]
Leadership[1]- 1 Rank in Prescriptions over the last 5 yrs.- Youngest in the Top 5 of the IPM- 4 By value in the IPM- 4 Consumer Healthcare brands Market ranked1 in their categories
| S.No. | Name | Current Price (Rs.) | Price to Earning | Market Capitalization (Rs.Cr.) | Dividend yield (%) | Net Profit latest quarter (Rs.Cr.) | YOY Quarterly profit growth (%) | Sales latest quarter (Rs.Cr.) | YOY Quarterly sales growth (%) | Return on capital employed (%) | Sales (Rs.Cr.) | OPM (%) | Profit after tax (Rs.Cr.) | Profit after tax latest quarter (Rs.Cr.) | Price to book value | Return on assets (%) | Debt to equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Sun Pharma.Inds. | 1777.00 | 36.83 | 426361.83 | 0.92 | 3124.95 | 2.56 | 14478.31 | 8.93 | 20.21 | 54964.01 | 30.12 | 11543.96 | 3117.95 | 5.48 | 12.97 | 0.07 |
| 2. | Divi's Lab. | 6674.85 | 71.24 | 177196.28 | 0.45 | 689.00 | 35.10 | 2715.00 | 16.12 | 20.44 | 10029.00 | 32.37 | 2485.00 | 689.00 | 11.53 | 13.53 | 0.01 |
| 3. | Torrent Pharma. | 4012.00 | 62.68 | 135784.27 | 0.80 | 591.00 | 32.49 | 3302.00 | 14.30 | 27.05 | 12248.00 | 32.60 | 2166.53 | 600.17 | 16.08 | 13.26 | 0.33 |
| 4. | Cipla | 1487.90 | 22.10 | 120188.25 | 0.87 | 1353.37 | 3.73 | 7589.44 | 7.64 | 22.72 | 28349.57 | 25.40 | 5441.14 | 1351.17 | 3.69 | 14.72 | 0.01 |
| 5. | Dr Reddy's Labs | 1257.00 | 18.17 | 104913.07 | 0.64 | 1336.80 | 7.28 | 8828.30 | 9.83 | 22.69 | 34310.00 | 24.64 | 5772.20 | 1347.10 | 2.92 | 12.95 | 0.16 |
| 6. | Lupin | 2205.15 | 23.30 | 100731.02 | 0.55 | 1484.83 | 73.34 | 7047.51 | 24.23 | 21.30 | 24750.69 | 27.25 | 4324.63 | 1477.92 | 5.13 | 12.41 | 0.32 |
| 7. | Zydus Lifesci. | 934.20 | 18.72 | 94002.40 | 1.18 | 1238.60 | 40.92 | 6123.20 | 16.92 | 24.31 | 24493.90 | 31.10 | 5029.35 | 1283.60 | 3.69 | 14.64 | 0.38 |
| 8. | Mankind Pharma | 2259.25 | 55.96 | 93262.95 | 0.04 | 458.90 | -25.18 | 2608.78 | 2.54 | 15.00 | 9691.14 | 26.72 | 1666.14 | 458.90 | 6.01 | 9.57 | 0.47 |
| – | Median: 150 Co. | 414.8 | 30.85 | 1769.05 | 0.11 | 13.03 | 12.32 | 157.2 | 10.56 | 14.95 | 582.87 | 15.96 | 44.55 | 13.73 | 3.15 | 8.6 | 0.22 |
Standalone figures in ₹ crores
| Dec 2022 | Dec 2023 | Dec 2024 | Jun 2023 | Jun 2024 | Jun 2025 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 1,936 | 2,209 | 2,414 | 2,092 | 2,413 | 2,541 | 1,872 | 2,007 | 2,127 | 2,258 | 2,260 | 2,544 | 2,609 |
Expenses | 1,563 | 1,636 | 1,668 | 1,594 | 1,837 | 1,868 | 1,491 | 1,482 | 1,650 | 1,735 | 1,662 | 1,781 | 1,916 |
Operating Profit | 374 | 573 | 746 | 498 | 576 | 673 | 381 | 526 | 477 | 522 | 598 | 763 | 693 |
Other Income | 32 | 92 | 70 | 87 | 125 | 64 | 42 | 109 | 219 | 69 | 84 | 139 | 78 |
Profit before tax | 326 | 571 | 525 | 514 | 603 | 494 | 355 | 543 | 429 | 517 | 601 | 810 | 525 |
Tax % | 24% | 15% | 22% | 20% | 16% | 16% | 21% | 14% | 11% | 19% | 21% | 20% | 13% |
Net Profit | 249 | 487 | 412 | 409 | 506 | 413 | 281 | 468 | 382 | 420 | 473 | 645 | 459 |
EPS in Rs | 6.21 | 12.16 | 9.99 | 10.22 | 12.62 | 10.00 | 7.01 | 11.68 | 9.27 | 10.49 | 11.80 | 16.11 | 11.12 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
Sales | 3,918 | 3,829 | 4,794 | 5,530 | 7,486 | 8,127 | 8,629 | 9,498 | 9,691 |
Expenses | 3,141 | 3,124 | 3,550 | 4,151 | 5,644 | 6,429 | 6,358 | 6,930 | 7,102 |
Operating Profit | 778 | 705 | 1,244 | 1,379 | 1,842 | 1,698 | 2,272 | 2,567 | 2,589 |
Other Income | 209 | 64 | 94 | 148 | 200 | 163 | 369 | 550 | 432 |
Interest | 18 | 40 | 11 | 8 | 48 | 28 | 17 | 372 | 656 |
Depreciation | 28 | 38 | 62 | 78 | 123 | 270 | 335 | 378 | 392 |
Profit before tax | 941 | 691 | 1,265 | 1,440 | 1,871 | 1,563 | 2,289 | 2,367 | 1,972 |
Net Profit | 694 | 514 | 958 | 1,084 | 1,389 | 1,248 | 1,876 | 1,945 | 1,666 |
EPS in Rs | 17.33 | 12.83 | 23.92 | 27.07 | 34.68 | 31.16 | 46.84 | 47.15 | 40.38 |
Dividend Payout % | 0% | 0% | 32% | 0% | 0% | 0% | 0% | 0% | – |
Standalone figures in ₹ crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 41 | 41 |
Reserves | 2,957 | 3,025 | 3,611 | 4,694 | 6,500 | 7,744 | 9,663 | 14,599 | 15,469 |
Borrowings | 360 | 190 | 3 | 101 | 688 | 5 | 24 | 7,254 | 7,248 |
Other Liabilities | 652 | 596 | 877 | 1,045 | 1,710 | 1,583 | 1,790 | 1,934 | 2,104 |
Total Liabilities | 4,009 | 3,851 | 4,531 | 5,880 | 8,939 | 9,371 | 11,516 | 23,828 | 24,862 |
Fixed Assets | 534 | 778 | 945 | 987 | 2,927 | 3,142 | 3,552 | 3,471 | 3,393 |
Gross Block | 612 | 893 | 1,117 | 1,227 | 3,292 | 3,776 | 4,578 | 4,845 | – |
Accumulated Depreciation | 78 | 116 | 172 | 240 | 366 | 633 | 1,027 | 1,375 | – |
CWIP | 322 | 211 | 148 | 166 | 387 | 495 | 209 | 207 | 248 |
Investments | 1,402 | 1,698 | 1,784 | 2,397 | 2,526 | 3,102 | 4,215 | 16,683 | 17,611 |
Other Assets | 1,751 | 1,164 | 1,655 | 2,330 | 3,100 | 2,632 | 3,540 | 3,467 | 3,610 |
Total Assets | 4,009 | 3,851 | 4,531 | 5,880 | 8,939 | 9,371 | 11,516 | 23,828 | 24,862 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
Cash from Operating Activity | 540 | 537 | 960 | 1,022 | 821 | 1,799 | 1,983 | 2,322 |
Cash from Investing Activity | -516 | -306 | -396 | -1,127 | -1,360 | -1,041 | -1,919 | -12,179 |
Cash from Financing Activity | 8 | -240 | -559 | 89 | 579 | -710 | -9 | 9,845 |
Net Cash Flow | 31 | -9 | 5 | -16 | 40 | 48 | 55 | -11 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
Debtor Days | 23 | 13 | 32 | 24 | 23 | 22 | 33 | 34 |
Inventory Days | 120 | 126 | 124 | 169 | 183 | 132 | 160 | 153 |
Days Payable | 115 | 101 | 113 | 122 | 133 | 103 | 75 | 79 |
Cash Conversion Cycle | 27 | 38 | 43 | 72 | 73 | 52 | 118 | 108 |
Working Capital Days | 95 | 44 | 41 | 42 | 26 | 40 | 55 | -48 |
ROCE % | – | 22% | 36% | 33% | 30% | 21% | 24% | 15% |
Direct from BSE filings, auto-summarised
External media mentions & references
Editorial & research coverage
Nov 2025
Aug 2025
May 2025
Jan 2025
Nov 2024
Sep 2024
Aug 2024
Aug 2024
Aug 2024
Jul 2024
May 2024
Feb 2024
Jan 2024
Nov 2023
Aug 2023
Jun 2023
Stock Analysis
Mankind Pharma Limited is a prominent Indian pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical formulations and consumer healthcare products across various therapeutic areas.
Based on past performance, key growth drivers include strong domestic market presence, outperformance in chronic therapies, expansion into international markets, and consolidation of acquisitions like Bharat Serums & Vaccines (BSV). The company focuses on R&D and brand strength.
Currently no data available for Order Book.
The company has faced several regulatory penalty orders related to GST and excise duties, though management has appealed these and stated no material impact.
The company has scheduled a board meeting for February 3, 2026, to approve Q3 FY26 results, with the trading window closing from January 1, 2026.
Corporate Announcements
